Navigation Links
Bortezomib for salvage therapy against progressive myeloma

Despite the initial efficacy of these therapies against multiple myeloma (MM), relapse is invariably the rule. Bortezomib (Velcade, formerly PS-341, Millennium, USA) is a novel first-class agent that inhibits the proteasome, a // multicatalytic cellular enzyme whose activity entails several molecular mechanisms, including, in particular, the NF-kB pathway.

Currently, bortezomib, alone or in combination with dexamethasone and doxorubicin, is under investigation as first-line and maintenance therapy. However, previous studies on advanced disease included a mixture of patients with multiple and heterogeneous previous regimens. Therefore, in order to obtain more careful information about the efficacy and tolerability of this drug in more homogeneously and less heavily pre-treated patients, researchers from Italy focused on the effects of bortezomib on a selected cohort of MM patients who had progressive disease after previous treatments including exclusively AuSCT and thalidomide. They focused on the effects of bortezomib as third line treatment (second salvage therapy) in a very homogeneous group of MM patients induced by AuSCT and relapsed or refractory after thalidomide employed as second line treatment (first salvage therapy).

For the study to be published in the journal Leukemia Research (available online 18 August 2005), twenty-one patients with multiple myeloma, all relapsed after frontline autologous stem cell transplantation and all relapsed again after or resistant to thalidomide (employed as second line treatment) received bortezomib without adjunct of steroids as third line therapy. Three patients died of progressive disease during the first 2 cycles with bortezomib. Eighteen patients received at least 2 cycles and were evaluated for response. According to EBMT criteria, 2 complete (negative immunofixation) and 7 partial remissions were achieved. Duration of response lasted from 2 to 14+ months. Grades 3?4 toxicities (thrombocytopeni a, leucopenia, peripheral neuropathy and vasculitis) were observed in 7 patients, but no patient interrupted the treatment due to side effects.

The study indicates that the use of bortezomib, in this specific setting, is generally safe and may be effective in a relevant proportion of cases. The authors conclude that bortezomib alone may induce high quality responses as third line salvage therapy with acceptable toxicity in a significant proportion of homogeneously pre-treated myeloma patients with progressive disease after autologous transplantation and thalidomide.
'"/>




Related medicine news :

1. Acupuncture May Help Chemotherapy Side Effects
2. Antioxidants protect health tissue in people undergoing radiation therapy.
3. Distraction therapy found very effective in postoperative patients
4. Acupuncture superseeds massage therapy for short term relief of pain
5. Ovarian cancer in relationship with Hormone therapy
6. New therapy better at increasing bone density
7. Gene therapy - Aim to improve blood flow
8. Gene therapy restores sight
9. Heat therapy relieves back pain
10. Radiotherapy helps in colon cancer
11. New therapy for pimples
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2016)... ... , ... When an Au Pair comes all the way around the world to ... and they are often worried things won’t go well. More often than not, however, they ... Pair of the Year winner’s all commented how their Au Pairs have become a part ...
(Date:2/12/2016)... Los Angeles, CA (PRWEB) , ... February 12, 2016 , ... ... da Vinci-assisted hernia surgeries are beginning to account for a significant portion of hernia ... Dr. Shirin Towfigh of the Beverly Hills Hernia Center notes that this trend has ...
(Date:2/12/2016)... (PRWEB) , ... February 12, ... ... Foundation today announced a new initiative—the Siemens Foundation-PATH Ingenuity Fellowships—to develop the ... partnership will recruit top students from U.S. universities who will draw from ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... 2016 — 1:30 p.m. – 3:00 p.m. EST, http://www.fdanews.com/fixeddosecombination ... life cycle of pharmaceutical products, garnering increased attention from all stakeholders in the ...
(Date:2/12/2016)... ... February 12, 2016 , ... Coco Libre, the maker of coconut water ... LA GRAMMY’s Style Lounge Event. Coco Libre will offer musicians and celebrities the company’s ... big event. The invitation-only gifting suite, held this year at the W Hollywood Hotel, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... 12, 2016  Sequent Medical, Inc. announced today that ... evaluate the safety and effectiveness of the WEB™ Aneurysm ... intracranial aneurysms.  Prof Laurent Spelle , MD, Head ... Paris, France and Principal Investigator of the ... France and Germany.  Although patients with ruptured ...
(Date:2/12/2016)... 2016  OMS Supply, a large provider of oral ... today the recent launching of their new company website. ... features that enhance the user experience and enable practitioners ... --> --> Despite the ... that started in early 2016, they have already made ...
(Date:2/11/2016)... Feb. 11, 2016 - ... in Personalized Medicine and Cancer Therapy. - European ... Diagnostic Testing Markets. - Key Diagnostic Testing Markets. ... Molecular Diagnostics in Genetic Testing. - Molecular Diagnostics ... - Over-the-Counter Diagnostic Products World Markets. - ...
Breaking Medicine Technology: